Form 4: Aclaris Therapeutics Director Andrew Powell Reports Stock Unit Vesting
SEC Form 4 Filing
Director Andrew Powell reports the vesting of 4,660 restricted stock units convertible to common stock in Aclaris Therapeutics.
Summary
- On June 1, 2024, Andrew Powell, a director of Aclaris Therapeutics, Inc., had 4,660 restricted stock units vest.
- These units convert into 4,660 shares of Aclaris Therapeutics common stock.
- Following the transaction, Powell directly owns 33,523 shares of common stock.
- The report was filed on June 4, 2024.
- A power of attorney was executed on May 18, 2024, granting authority to Kevin Balthaser, Matthew Rothman, Mark Ballantyne, David Brinton, and Robin Lee to file SEC forms on Powell's behalf.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of insider activity and doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 05/18/2024 | Date of Power of Attorney execution. |
| 06/01/2024 | Date of transaction: Restricted Stock Units vested. |
| 06/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.